Prashanth Reddy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11372202/publications.pdf

Version: 2024-02-01

933264 1372474 10 711 10 10 citations g-index h-index papers 10 10 10 710 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Euro <scp>I</scp> nf: <scp>A</scp> <scp>M</scp> ulticenter <scp>C</scp> omparative <scp>O</scp> bservational <scp>S</scp> tudy of <scp>A</scp> pomorphine and <scp>L</scp> evodopa <scp>I</scp> nfusion in <scp>P</scp> arkinson's <scp>D</scp> isease. Movement Disorders, 2015, 30, 510-516.	2.2	203
2	EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease. Movement Disorders, 2019, 34, 353-365.	2.2	126
3	Chronic Subcutaneous Infusion Therapy with Apomorphine in Advanced Parkinson's Disease Compared to Conventional Therapy: A Real Life Study of Non Motor Effect. Journal of Parkinson's Disease, 2011, 1, 197-203.	1.5	107
4	Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease. Brain Stimulation, 2016, 9, 78-85.	0.7	86
5	Intrajejunal Levodopa Versus Conventional Therapy in Parkinson Disease. Clinical Neuropharmacology, 2012, 35, 205-207.	0.2	51
6	Perceptions of symptoms and expectations of advanced therapy for Parkinson's disease: preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson's disease (PRO-APD). Health and Quality of Life Outcomes, 2014, 12, 11.	1.0	41
7	Short-term quality of life after subthalamic stimulation depends on non-motor symptoms in Parkinson's disease. Brain Stimulation, 2018, 11, 867-874.	0.7	36
8	Subthalamic Stimulation Improves Quality of Life of Patients Aged 61 Years or Older With Short Duration of Parkinson's Disease. Neuromodulation, 2018, 21, 532-540.	0.4	26
9	Noninvasive options for â€`wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists. Neurodegenerative Disease Management, 2018, 8, 349-360.	1.2	22
10	Daytime apomorphine infusion combined with transdermal Rotigotine patch therapy is tolerated at 2 years: A 24-h treatment option in Parkinson's disease. Basal Ganglia, 2013, 3, 127-130.	0.3	13